InfuSystem (INFU) Board approves new $20 million share repurchase program
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
InfuSystem Holdings, Inc. announced that its Board of Directors has approved a new stock repurchase program authorizing the Company to buy back up to $20 million of its outstanding common stock. The program will run from July 1, 2026 through June 30, 2028.
This new authorization will supersede the current repurchase program, which is scheduled to expire on June 30, 2026. Under the current authorization, InfuSystem repurchased approximately 1.6 million shares for about $11.9 million through March 31, 2026, reflecting ongoing use of buybacks as a capital allocation tool.
Positive
- None.
Negative
- None.
Insights
InfuSystem extends its capital return strategy with a new $20 million buyback authorization.
InfuSystem has approved a stock repurchase program authorizing up to $20 million in common stock repurchases from July 1, 2026 through June 30, 2028. This follows an existing authorization under which the company repurchased about 1.6 million shares for roughly $11.9 million through March 31, 2026.
Repurchases may be executed via open market purchases, private transactions or other methods in line with Rule 10b-18 under the Exchange Act. Management highlights the program as part of an established buyback policy and cites balance sheet and cash flow strength as support.
The CEO also notes that strategic investments for sustainable growth remain the top capital priority, with buybacks providing flexibility to act when valuations are considered attractive. Actual impact on share count and per-share metrics will depend on future execution levels and market conditions.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
New repurchase authorization: $20 million
Program period start: July 1, 2026
Program period end: June 30, 2028
+2 more
5 metrics
New repurchase authorization
$20 million
Maximum common stock buybacks authorized July 1, 2026–June 30, 2028
Program period start
July 1, 2026
Start date for new stock repurchase program
Program period end
June 30, 2028
End date for new stock repurchase program
Shares repurchased to date
1.6 million shares
Shares repurchased under current authorization through March 31, 2026
Amount spent under current plan
$11.9 million
Total spent on repurchases under existing authorization through March 31, 2026
Key Terms
stock repurchase program, Rule 10b-18, Regulation FD Disclosure, forward-looking statements, +1 more
5 terms
stock repurchase program financial
"the Company’s Board of Directors has approved a stock repurchase program authorizing the Company to repurchase up to $20 million"
A stock repurchase program is when a company buys back its own shares from the market. This can make each remaining share more valuable and shows that the company believes its stock is a good investment. It’s like a business treating its shares like a limited resource, hoping to boost confidence and share prices.
Rule 10b-18 regulatory
"in accordance with applicable federal securities laws, including Rule 10b-18 under the Securities Exchange Act of 1934"
Rule 10b-18 is a regulation that sets strict rules for how a company's executives and employees can buy back their own company's stock from the market. It helps ensure that these buybacks happen in a fair and transparent way, reducing the chance of market manipulation. This is important for investors because it offers protection against unfair practices and promotes confidence in the integrity of the stock market.
Regulation FD Disclosure regulatory
"Item 7.01 - Regulation FD Disclosure On May 18, 2026, InfuSystem Holdings, Inc."
Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.
forward-looking statements regulatory
"Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
durable medical equipment technical
"facilitating outpatient care for durable medical equipment manufacturers and health care providers"
Durable medical equipment (DME) includes long-lasting devices used to help people manage health conditions and improve mobility, such as wheelchairs, hospital beds, and oxygen machines. These items are designed to be reused and are often covered by health insurance. For investors, DME represents a steady market because demand remains consistent as populations age and healthcare needs grow.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported): May 12, 2026
___________________________________
(Exact name of registrant as specified in its charter)
___________________________________
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification Number) | ||||||
(Address of principal executive offices) (Zip Code) | ||||||||
( | ||||||||
(Registrant's telephone number, including area code) | ||||||||
Not Applicable | ||||||||
(Former Name or Former Address, if Changed Since Last Report) | ||||||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act: | ||||||||
Title of Each Class | Trading Symbol(s) | Name of Each Exchange on which Registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 - Regulation FD Disclosure
On May 18, 2026, InfuSystem Holdings, Inc. (the “Company”) issued a press release announcing that the Company’s Board of Directors has approved a stock repurchase program authorizing the Company to repurchase up to $20 million of the Company’s outstanding common stock starting on July 1, 2026 and running through through June 30, 2028. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information furnished in this Item 7.01 — “Regulation FD Disclosure” of this Current Report on Form 8-K and the press release attached hereto as Exhibit 99.1 shall not be deemed “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of such section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.
Item 9.01 - Financial Statements and Exhibits
(d) Exhibits
Exhibit No. | Description | |||||||
99.1 | Press Release of InfuSystem Holdings, Inc. dated May 18, 2026 | |||||||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
INFUSYSTEM HOLDINGS, INC. | |||||
By: | /s/ Barry Steele | ||||
Barry Steele | |||||
Chief Financial Officer | |||||
Dated: May 18, 2026
Exhibit 99.1
 | InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 (248) 291-1210 | Contact: Barry Steele Chief Financial Officer (248) 260-2211 | ||||||
InfuSystem Announces $20 Million Stock Repurchase Program
Rochester Hills, Michigan, May 18, 2026 - InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today that the Company’s Board of Directors has approved a stock repurchase program authorizing the Company to repurchase up to $20 million of the Company’s outstanding common stock starting on July 1, 2026 and running through June 30, 2028. The program will supersede the previous authorization which is set to expire on June 30, 2026. Under the current authorization, the Company repurchased approximately 1.6 million shares of stock for approximately $11.9 million though March 31, 2026. Repurchases will be made through open market purchases, private transactions, or otherwise in accordance with applicable federal securities laws, including Rule 10b-18 under the Securities Exchange Act of 1934 (the “Exchange Act”).
Carrie Lachance, Chief Executive Officer of InfuSystem, said, “This authorization carries on the Company’s established buyback policy which we have used when appropriate to enhance shareholder value. I believe the stock repurchase program demonstrates our confidence in being able to continue to execute with discipline, deliver profitable growth and drive long term value for the rest of 2026 and beyond. It also reflects the strength of our balance sheet and cash flows. Our top priority for use of capital remains making strategic investments that position the Company for sustainable growth, although this program provides us with the flexibility to be opportunistic in repurchasing shares when valuations become attractive.”
About InfuSystem Holdings, Inc.
InfuSystem Holdings, Inc. (NYSE American: INFU), is a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-platform model. The first platform is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient Services segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second platform, Device Solutions, supports the Patient Services platform and leverages strong service orientation to win incremental business from its direct payer clients. The Device Solutions segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Headquartered in Rochester Hills, Michigan, the Company delivers local, field-based customer support and also operates Centers of Excellence in Michigan, Kansas, California, Massachusetts, Texas and Ontario, Canada.
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended, such as statements relating to future actions, business plans, strategic partnerships, growth initiatives, objectives and prospects, future operating or financial performance, guidance and expected new business relationships and the terms thereof (including estimated potential revenue under new or existing contracts). The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “goal,” “expect,” “strategy,” “future,” “likely,” variations of such words, and other similar expressions, as they relate to the Company, are intended to identify forward-looking statements. Forward-looking statements are subject to factors, risks and uncertainties that could cause actual results to differ materially, including, but not limited to, our ability to successfully execute on our growth initiatives and strategic partnerships, our ability to enter into definitive agreements for new business relationships on expected terms or at all, our ability to generate estimated potential revenue amounts under new or existing contracts, our dependence on estimates of collectible revenue, potential litigation, changes in third-party reimbursement processes, changes in law, global financial conditions and recessionary risks, rising inflation and interest rates, supply chain disruptions, systemic pressures in the banking sector, including disruptions to credit markets, contributions from acquired businesses or new business lines, products or services and other risk factors disclosed in the Company’s most recent annual report on Form 10-K and, to the extent applicable, quarterly reports on Form 10-Q. Our strategic partnerships are subject to similar factors, risks and uncertainties. All forward-looking statements made in this press release speak only as of the date hereof. We do not undertake any obligation to update any forward-looking statements to reflect future events or circumstances, except as required by law.
Additional information about InfuSystem Holdings, Inc. is available at www.infusystem.com.
####
FAQ
What did InfuSystem (INFU) announce regarding its stock repurchase program?
InfuSystem’s Board approved a new stock repurchase program authorizing buybacks of up to $20 million of common stock. The program is intended to continue the company’s established use of share repurchases as a capital allocation tool alongside strategic growth investments.
How much stock has InfuSystem repurchased under its current authorization?
Under the current authorization, InfuSystem repurchased approximately 1.6 million shares for about $11.9 million through March 31, 2026. This history shows the company has actively used buybacks prior to approving the new $20 million program that will supersede the existing one.
When does InfuSystem’s existing stock repurchase authorization expire?
InfuSystem’s existing stock repurchase authorization is set to expire on June 30, 2026. The newly approved $20 million program will supersede this prior authorization and extend the potential repurchase period through June 30, 2028, subject to market conditions and company decisions.
How will InfuSystem execute repurchases under the new program?
InfuSystem plans to conduct repurchases through open market purchases, private transactions, or other methods permitted by law. Transactions will follow Rule 10b-18 under the Exchange Act, which provides a framework for issuer share repurchase activity in U.S. markets.
What does InfuSystem’s CEO say about the purpose of the buyback program?
The CEO states the authorization continues InfuSystem’s established buyback policy aimed at enhancing shareholder value. She highlights confidence in disciplined execution, profitable growth, and strong cash flows, while emphasizing that strategic growth investments remain the primary capital deployment priority.